Trial Profile
A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Galunisertib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 Aug 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Safety and tolerability results (n=42) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 15 May 2019 According to a Eli Lilly media release, data from this trial will be presented at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019.